Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ImmunoGen, Inc.
In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely to shepherd an exit from the current doldrums, though.
The European Medicines Agency’s CHMP was set to adopt opinions on SK Bioscience’s COVID-19 vaccine and Mycovia/Gedeon’s Vivjoa for vulvovaginal candidiasis during its September meeting, but both marketing authorization filings were voluntarily withdrawn.
Mariana Oncology closed a $175m series A venture capital round to fund its first clinical trial, for MC-339 in small-cell lung cancer, as well as its manufacturing and pipeline-building activities.
Emergex CEO and ex-research director at the University of Oxford, Thomas Rademacher, spoke with Scrip about the myth of the “Wuhan virus” and why synthetic T-cell adaptive vaccines are expected to be superior to RNA/mRNA ones. More partners are being sought for additional delivery mechanisms, the founder of the UK-based, clinical-stage biotech says in this podcast interview.
- Controlled Release
- Site Specific
- Drug Delivery
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.